Pawan Bir Kohli

Identification of imidazo-pyrrolopyridines as novel and potent JAK1 inhibitors.

Bohdan Waszkowycz, Jane R Kenny, Charles Eigenbrot, 2012, Journal of medicinal chemistry.

RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases

Adam R. Johnson, M. van Lookeren Campagne, J. Webster, 2019, Cell Death & Differentiation.

Structure of human RIPK1 kinase domain in complex with GNE684

Adam R. Johnson, M. van Lookeren Campagne, J. Webster, 2019 .

Identification of C-2 hydroxyethyl imidazopyrrolopyridines as potent JAK1 inhibitors with favorable physicochemical properties and high selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Ignacio Aliagas, 2013, Journal of medicinal chemistry.

Discovery and optimization of C-2 methyl imidazopyrrolopyridines as potent and orally bioavailable JAK1 inhibitors with selectivity over JAK2.

Jane R Kenny, Philippe Bergeron, Tian Jin, 2012, Journal of medicinal chemistry.

Structure of the pseudokinase–kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition

Adam R. Johnson, M. Ultsch, C. Eigenbrot, 2014, Proceedings of the National Academy of Sciences.

Identification of an imidazopyridine scaffold to generate potent and selective TYK2 inhibitors that demonstrate activity in an in vivo psoriasis model.

Adam R. Johnson, Jun Liang, J. DeVoss, 2017, Bioorganic & medicinal chemistry letters.

RIP1 inhibition blocks inflammatory diseases but not tumor growth or metastases

Adam R. Johnson, M. van Lookeren Campagne, J. Webster, 2019, Cell Death & Differentiation.